09:22 AM EST, 02/27/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) reported a Q4 net loss Thursday of $1.27 per diluted share, narrower than a loss of $1.46 a year earlier.

Analysts polled by FactSet expected a loss of $1.33.

Collaboration revenue for the quarter ended Dec. 31 was $12.9 million, compared with a revenue loss of $1.9 million a year earlier.

Analysts surveyed by FactSet expected $8.6 million.

The company said it had cash, cash equivalents and marketable securities of $861.7 million as of Dec. 31, which is expected to fund operations into H1 2027.

Intellia shares were rising past 5% in recent premarket activity.